MedPath

Irinotecan

Generic Name
Irinotecan
Brand Names
Camptosar, Onivyde, Onivyde pegylated liposomal (previously known as Onivyde)
Drug Type
Small Molecule
Chemical Formula
C33H38N4O6
CAS Number
97682-44-5
Unique Ingredient Identifier
7673326042
Background

Irinotecan is an antineoplastic enzyme inhibitor primarily used in the treatment of colorectal cancer. It is a derivative of camptothecin that inhibits the action of topoisomerase I. Irinotecan prevents religation of the DNA strand by binding to topoisomerase I-DNA complex, and causes double-strand DNA breakage and cell death. It is a derivative of camptothecin. Irinotecan was approved for the treatment of advanced pancreatic cancer in October, 2015 (irinotecan liposome injection, trade name Onivyde).

Indication

For the treatment of metastatic colorectal cancer (first-line therapy when administered with 5-fluorouracil and leucovorin). Also used in combination with cisplatin for the treatment of extensive small cell lung cancer. Irinotecan is currently under investigation for the treatment of metastatic or recurrent cervical cancer. Also used in combination with fluorouracil and leucovorin for the treatment of patients with metastatic adenocarcinoma of the pancreas after disease progression following gemcitabine-based therapy.

Associated Conditions
Esophageal Cancer, Ewing's Sarcoma, Gastric Cancer, High Grade Glioma: Glioblastoma (GBM), Metastatic Cervical Cancer, Non-Small Cell Lung Cancer (NSCLC), Ovarian Cancer, Pancreatic Cancer, Rhabdomyosarcomas, Small Cell Lung Cancer (SCLC), Stage IV Colorectal Cancer, Recurrent, metastatic Colorectal carcinoma, Refractory, metastatic Pancreatic adenocarcinoma
Associated Therapies
-
Clinical Trials
Related News

Efficacy and Tolerance of Maintenance Therapy in Patients With Incurable Advanced Colorectal Cancer

Phase 2
Conditions
Incurable Colorectal Cancer
RAS-wild-type
Interventions
Drug: Cetuximab
Drug: irinotecan
Drug: fluorouracil
First Posted Date
2014-02-25
Last Posted Date
2015-11-18
Lead Sponsor
Tianshu Liu
Target Recruit Count
54
Registration Number
NCT02071069
Locations
🇨🇳

Zhongshan Hospital Affiliated to Fudan University, Shanghai, Shanghai, China

Genetically Modified Stem Cells and Irinotecan Hydrochloride in Treating Patients With Recurrent High-Grade Gliomas

Phase 1
Withdrawn
Conditions
Adult Anaplastic Astrocytoma
Adult Anaplastic Oligodendroglioma
Adult Giant Cell Glioblastoma
Adult Glioblastoma
Adult Gliosarcoma
Recurrent Adult Brain Tumor
Interventions
Biological: carboxylesterase-expressing allogeneic neural stem cells
Drug: irinotecan hydrochloride
Other: laboratory biomarker analysis
First Posted Date
2014-02-05
Last Posted Date
2014-06-02
Lead Sponsor
City of Hope Medical Center
Registration Number
NCT02055196
Locations
🇺🇸

City of Hope Medical Center, Duarte, California, United States

PARP Inhibitor BMN-673 and Temozolomide or Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic Solid Tumors

Phase 1
Completed
Conditions
Unspecified Adult Solid Tumor
Metastatic Cancer
Interventions
Drug: PARP inhibitor BMN-673
Drug: temozolomide
Drug: irinotecan hydrochloride
Other: pharmacological study
Other: laboratory biomarker analysis
First Posted Date
2014-01-30
Last Posted Date
2022-09-26
Lead Sponsor
Jonsson Comprehensive Cancer Center
Target Recruit Count
44
Registration Number
NCT02049593
Locations
🇺🇸

Jonsson Comprehensive Cancer Center, Los Angeles, California, United States

Combination Chemotherapy Before and After Surgery in Treating Patients With Localized Pancreatic Cancer

Phase 2
Active, not recruiting
Conditions
Stage I Pancreatic Cancer
Stage IIB Pancreatic Cancer
Acinar Cell Adenocarcinoma of the Pancreas
Stage IIA Pancreatic Cancer
Duct Cell Adenocarcinoma of the Pancreas
Interventions
Drug: oxaliplatin
Drug: leucovorin calcium
Drug: irinotecan hydrochloride
Drug: fluorouracil
Procedure: therapeutic conventional surgery
Other: laboratory biomarker analysis
First Posted Date
2014-01-28
Last Posted Date
2023-11-13
Lead Sponsor
Yale University
Target Recruit Count
46
Registration Number
NCT02047474
Locations
🇺🇸

Smilow Cancer Hospital at St. Francis Hospital, Hartford, Connecticut, United States

🇺🇸

Smilow Cancer Hospital at North Haven, North Haven, Connecticut, United States

🇺🇸

Yale University, New Haven, Connecticut, United States

and more 6 locations

Phase II Study of Zaltrap and Chemotherapy for Advanced Resectable Colorectal Cancer

Phase 2
Withdrawn
Conditions
Adenocarcinoma of the Rectum
Adenocarcinoma of the Colon
Interventions
Drug: Leucovorin
Drug: Oxaliplatin
Drug: 5-FU
Drug: Irinotecan
First Posted Date
2014-01-27
Last Posted Date
2017-01-25
Lead Sponsor
Weill Medical College of Cornell University
Registration Number
NCT02046538
Locations
🇺🇸

Weill Cornell Medical College, New York city, New York, United States

ESP1/SARC025 Global Collaboration: A Phase I Study of a Combination of the PARP Inhibitor, Niraparib and Temozolomide and/or Irinotecan Patients With Previously Treated, Incurable Ewing Sarcoma

Phase 1
Completed
Conditions
Ewing Sarcoma
Interventions
Drug: niraparib
Drug: Irinotecan
Drug: Temozolomide
First Posted Date
2014-01-23
Last Posted Date
2021-01-12
Lead Sponsor
Sarcoma Alliance for Research through Collaboration
Target Recruit Count
34
Registration Number
NCT02044120
Locations
🇺🇸

Children's Hospital of Los Angeles, Los Angeles, California, United States

🇺🇸

Seattle's Children Cancer Center, Seattle, Washington, United States

🇬🇧

University College London Hospital, London, United Kingdom

and more 2 locations

131I-MIBG Alone VS. 131I-MIBG With Vincristine and Irinotecan VS131I-MIBG With Vorinostat

Phase 2
Completed
Conditions
Neuroblastoma
Interventions
Radiation: 131I-MIBG
Drug: Vincristine
Drug: Vorinostat
Drug: Irinotecan
First Posted Date
2014-01-14
Last Posted Date
2022-06-08
Lead Sponsor
New Approaches to Neuroblastoma Therapy Consortium
Target Recruit Count
114
Registration Number
NCT02035137
Locations
🇺🇸

Children Hospital of Colorado, Aurora, Colorado, United States

🇺🇸

Children's Hospital Boston, Boston, Massachusetts, United States

🇺🇸

University of North Carolina, Chapel Hill, North Carolina, United States

and more 11 locations

A Phase II Study of Irinotecan in 3 Line or More Therapy in Local Recurrence or Metastatic Breast Cancer

Phase 2
Conditions
Stage IIIB, IV, Recurrent, and Metastatic Breast Cancer
Interventions
Drug: irinotecan
First Posted Date
2014-01-08
Last Posted Date
2018-09-05
Lead Sponsor
Liaoning Tumor Hospital & Institute
Target Recruit Count
124
Registration Number
NCT02030678
Locations
🇨🇳

SunTao, Shenyang, Liaoning, China

A Study of BBI608 in Combination With Standard Chemotherapies in Adult Patients With Advanced Gastrointestinal Cancer

First Posted Date
2013-12-31
Last Posted Date
2023-11-15
Lead Sponsor
Sumitomo Pharma America, Inc.
Target Recruit Count
495
Registration Number
NCT02024607
Locations
🇺🇸

Parkview Research Center, Fort Wayne, Indiana, United States

🇺🇸

Emory University Winship Cancer Institute, Atlanta, Georgia, United States

🇺🇸

Indiana University Health Goshen Center for Cancer Care, Goshen, Indiana, United States

and more 12 locations

A Pilot, Prospective, Non-randomized Evaluation of the Safety of Anakinra Plus Standard Chemotherapy

Phase 1
Conditions
Pancreas Cancer
Interventions
Drug: anakinra
Drug: Oxaliplatin
Drug: Irinotecan
Drug: fluorouracil
First Posted Date
2013-12-27
Last Posted Date
2017-01-31
Lead Sponsor
Baylor Research Institute
Target Recruit Count
13
Registration Number
NCT02021422
Locations
🇺🇸

Baylor Sammons Cancer Center, Dallas, Texas, United States

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy